循环微小RNA-210对肾细胞癌的检测性能：一项Meta分析

Detection Performance of Circulating MicroRNA-210 for Renal Cell Carcinoma: a Meta-Analysis.

作者信息

Chen Yan, Wang Xiaoyan, Zhu Xuxiao, Shao Shengwen

出版信息

Clin Lab. 2018 Apr 1;64(4):569-576. doi: 10.7754/Clin.Lab.2017.171103.

DOI:10.7754/Clin.Lab.2017.171103

PMID:29739083

Abstract

BACKGROUND

Renal cell carcinoma (RCC) is the most common neoplasm of the adult kidney. miR-210 was a known oncogene with tumor-promoting effects in many types of cancer. This meta-analysis aimed to evaluate the potential diagnostic value of circulating miR-210.

METHODS

Relevant literature was collected from PubMed and Embase. Sensitivity, specificity, and diagnostic odds ratio (DOR) for miR-210 in the diagnosis of RCC were pooled using random effects models. Summary receiver operating characteristic (SROC) curve analysis and the area under the curve (AUC) were used to estimate the overall test performance.

RESULTS

This meta-analysis included seven studies with a total of 570 RCC patients and 415 healthy controls. For miR-210, the pooled sensitivity, specificity, and DOR to predict RCC patients were 0.74 (95% confidence interval [CI]: 0.70 - 0.77), 0.76 (95% CI: 0.71 - 0.80) and 8.81 (95% CI: 5.31 - 14.57), respectively. In addition, the AUC of miR-210 for the diagnosis of RCC is 0.81.

CONCLUSIONS

MiR-210 might be a potential novel biomarker in the diagnosis of renal cell carcinoma.

摘要

背景

肾细胞癌（RCC）是成人肾脏最常见的肿瘤。miR - 210是一种已知的致癌基因，在多种癌症中具有促进肿瘤的作用。本荟萃分析旨在评估循环miR - 210的潜在诊断价值。

方法

从PubMed和Embase收集相关文献。使用随机效应模型汇总miR - 210在RCC诊断中的敏感性、特异性和诊断比值比（DOR）。采用汇总受试者工作特征（SROC）曲线分析和曲线下面积（AUC）来估计总体检测性能。

结果

本荟萃分析纳入了7项研究，共570例RCC患者和415例健康对照。对于miR - 210，预测RCC患者的汇总敏感性、特异性和DOR分别为0.74（95%置信区间[CI]：0.70 - 0.77）、0.76（95%CI：0.71 - 0.80）和8.81（95%CI：5.31 - 14.57）。此外，miR - 210诊断RCC的AUC为0.81。